{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:55:07Z","timestamp":1793260507934,"version":"4.5.0"},"reference-count":52,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"\n Importance<\/jats:title>\n Whether ketamine is as effective as electroconvulsive therapy (ECT) among patients with major depressive episode remains unknown.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To systematically review and meta-analyze data about clinical efficacy and safety for ketamine and ECT in patients with major depressive episode.<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n PubMed, MEDLINE, Cochrane Library, and Embase were systematically searched using Medical Subject Headings (MeSH) terms and text keywords from database inception through April 19, 2022, with no language limits. Two authors also manually and independently searched all relevant studies in US and European clinical trial registries and Google Scholar.<\/jats:p>\n <\/jats:sec>\n \n Study Selection<\/jats:title>\n Included were studies that involved (1) a diagnosis of depression using standardized diagnostic criteria, (2) intervention\/comparator groups consisting of ECT and ketamine, and (3) depressive symptoms as an efficacy outcome using standardized measures.<\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n \n Data extraction was completed independently by 2 extractors and cross-checked for errors. Hedges\n g<\/jats:italic>\n standardized mean differences (SMDs) were used for improvement in depressive symptoms. SMDs with corresponding 95% CIs were estimated using fixed- or random-effects models. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline was followed.\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Efficacy outcomes included depression severity, cognition, and memory performance. Safety outcomes included serious adverse events (eg, suicide attempts and deaths) and other adverse events.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Six clinical trials comprising 340 patients (n\u2009=\u2009162 for ECT and n\u2009=\u2009178 for ketamine) were included in the review. Six of 6 studies enrolled patients who were eligible to receive ECT, 6 studies were conducted in inpatient settings, and 5 studies were randomized clinical trials. The overall pooled SMD for depression symptoms for ECT when compared with ketamine was \u22120.69 (95% CI, \u22120.89 to \u22120.48; Cochran\n Q<\/jats:italic>\n ,\n P<\/jats:italic>\n \u2009=\u2009.15;\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200939%), suggesting an efficacy advantage for ECT compared with ketamine for depression severity. Significant differences were not observed between groups for studies that assessed cognition\/memory or serious adverse events. Both ketamine and ECT had unique adverse effect profiles (ie, ketamine: lower risks for headache and muscle pain; ECT: lower risks for blurred vision, vertigo, diplopia\/nystagmus, and transient dissociative\/depersonalization symptoms). Limitations included low to moderate methodological quality and underpowered study designs.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Findings from this systematic review and meta-analysis suggest that ECT may be superior to ketamine for improving depression severity in the acute phase, but treatment options should be individualized and patient-centered.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2022.3352","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T11:06:57Z","timestamp":1666177617000},"page":"1162","source":"Crossref","is-referenced-by-count":134,"title":["Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode"],"prefix":"10.1001","volume":"79","author":[{"given":"Taeho Greg","family":"Rhee","sequence":"first","affiliation":[{"name":"Department of Psychiatry, School of Medicine, Yale University, New Haven, Connecticut"},{"name":"VA New England Mental Illness, Research, Education and Clinical Center (MIRECC), VA Connecticut Healthcare System, West Haven"},{"name":"Department of Public Health Sciences, School of Medicine, University of Connecticut, Farmington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Ryul","family":"Shim","sequence":"additional","affiliation":[{"name":"Department of Health and Medical Informatics, Kyungnam University College of Health Sciences, Changwon, Gyeongsangnam-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent P.","family":"Forester","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Geriatric Psychiatry, McLean Hospital, Belmont, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Nierenberg","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Harvard Medical School, Boston, Massachusetts"},{"name":"Dauten Family Center for Bipolar Treatment Innovation, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada"},{"name":"Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George I.","family":"Papakostas","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Harvard Medical School, Boston, Massachusetts"},{"name":"Dauten Family Center for Bipolar Treatment Innovation, Massachusetts General Hospital, Boston"},{"name":"Clinical Trials Network and Institute, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Krystal","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, School of Medicine, Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Sanacora","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, School of Medicine, Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel T.","family":"Wilkinson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, School of Medicine, Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"11","key":"yoi220067r3","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1001\/jamapsychiatry.2020.1818","article-title":"Prevalence of treatment for depression among US adults who screen positive for depression, 2007-2016.","volume":"77","author":"Rhee","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"yoi220067r4","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/YCO.0000000000000505","article-title":"Depression: more treatment but no drop in prevalence: how effective is treatment? and can we do better?","volume":"32","author":"Ormel","year":"2019","journal-title":"Curr Opin Psychiatry"},{"issue":"1","key":"yoi220067r5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3949\/ccjm.75.1.57","article-title":"The STAR*D study: treating depression in the real world.","volume":"75","author":"Gaynes","year":"2008","journal-title":"Cleve Clin J Med"},{"issue":"8","key":"yoi220067r6","doi-asserted-by":"publisher","first-page":"627","DOI":"10.2165\/00023210-200923080-00001","article-title":"STAR*D: revising conventional wisdom.","volume":"23","author":"Rush","year":"2009","journal-title":"CNS Drugs"},{"issue":"8","key":"yoi220067r7","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1176\/appi.ps.201300059","article-title":"A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013.","volume":"65","author":"Mrazek","year":"2014","journal-title":"Psychiatr Serv"},{"issue":"3-4","key":"yoi220067r8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jpsychires.2006.05.008","article-title":"The burden of severe depression: a review of diagnostic challenges and treatment alternatives.","volume":"41","author":"Nemeroff","year":"2007","journal-title":"J Psychiatr Res"},{"issue":"2","key":"yoi220067r9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/da.v39.2","article-title":"Pharmacological and somatic treatment effects on suicide in adults: a systematic review and meta-analysis.","volume":"39","author":"Wilkinson","year":"2022","journal-title":"Depress Anxiety"},{"issue":"7","key":"yoi220067r12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1177\/0004867419839139","article-title":"Royal Australian and New Zealand College of Psychiatrists professional practice guidelines for the administration of electroconvulsive therapy.","volume":"53","author":"Weiss","year":"2019","journal-title":"Aust N Z J Psychiatry"},{"issue":"10","key":"yoi220067r13","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.4088\/JCP.14r09528","article-title":"Response of depression to electroconvulsive therapy: a meta-analysis of clinical predictors.","volume":"76","author":"Haq","year":"2015","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"yoi220067r14","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1001\/jamapsychiatry.2017.1670","article-title":"Modern electroconvulsive therapy: vastly improved yet greatly underused.","volume":"74","author":"Sackeim","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"yoi220067r15","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m13186","article-title":"Characterization of the quality of electroconvulsive therapy among older Medicare beneficiaries.","volume":"81","author":"Rhee","year":"2020","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"yoi220067r16","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1176\/appi.ps.202000387","article-title":"Barriers to the implementation of electroconvulsive therapy (ECT): results from a nationwide survey of ECT practitioners.","volume":"72","author":"Wilkinson","year":"2021","journal-title":"Psychiatr Serv"},{"issue":"4","key":"yoi220067r17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients.","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatry"},{"issue":"10","key":"yoi220067r18","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.","volume":"170","author":"Murrough","year":"2013","journal-title":"Am J Psychiatry"},{"issue":"8","key":"yoi220067r19","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"yoi220067r20","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","article-title":"A consensus statement on the use of ketamine in the treatment of mood disorders.","volume":"74","author":"Sanacora","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"yoi220067r21","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation.","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am J Psychiatry"},{"key":"yoi220067r22","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.2147\/NDT","article-title":"Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies.","volume":"12","author":"Han","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"7","key":"yoi220067r23","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1017\/S0033291716000064","article-title":"Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.","volume":"46","author":"Kishimoto","year":"2016","journal-title":"Psychol Med"},{"issue":"6","key":"yoi220067r24","doi-asserted-by":"publisher","DOI":"10.3390\/ph13060116","article-title":"Pharmacological treatments for patients with treatment-resistant depression.","volume":"13","author":"Ruberto","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"yoi220067r25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","article-title":"Side-effects associated with ketamine use in depression: a systematic review.","volume":"5","author":"Short","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"yoi220067r26","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jad.2020.11.123","article-title":"Is ketamine an appropriate alternative to ECT for patients with treatment resistant depression? a systematic review.","volume":"281","author":"Veraart","year":"2021","journal-title":"J Affect Disord"},{"issue":"7","key":"yoi220067r27","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1001\/jamapsychiatry.2022.1074","article-title":"Evaluation of the trajectory of depression severity with ketamine and esketamine treatment in a clinical setting.","volume":"79","author":"Nikayin","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"yoi220067r28","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22f14451","article-title":"Insights for the use of ketamine from randomized controlled trials that compared ketamine with electroconvulsive therapy in severe depression.","volume":"83","author":"Andrade","year":"2022","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"yoi220067r29","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22ac14436","article-title":"Prioritizing patient preferences: a practical guide for tailoring treatment choices in interventional psychiatry.","volume":"83","author":"Berman","year":"2022","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"yoi220067r30","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med"},{"key":"yoi220067r31","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"yoi220067r35","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2019008","article-title":"Intervention meta-analysis: application and practice using R software.","volume":"41","author":"Shim","year":"2019","journal-title":"Epidemiol Health"},{"key":"yoi220067r36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpsychires.2020.01.002","article-title":"Antidepressant and neurocognitive effects of serial ketamine administration versus ECT in depressed patients.","volume":"123","author":"Basso","year":"2020","journal-title":"J Psychiatr Res"},{"issue":"5","key":"yoi220067r37","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/ijnp\/pyab088","article-title":"Racemic ketamine as an alternative to electroconvulsive therapy for unipolar depression: a randomized, open-label, non-inferiority trial (KetECT).","volume":"25","author":"Ekstrand","year":"2022","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"yoi220067r38","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.psychres.2013.12.008","article-title":"Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder.","volume":"215","author":"Ghasemi","year":"2014","journal-title":"Psychiatry Res"},{"key":"yoi220067r39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4103\/abr.abr_166_18","article-title":"Comparative effect of intravenous ketamine and electroconvulsive therapy in major depression: a randomized controlled trial.","volume":"8","author":"Kheirabadi","year":"2019","journal-title":"Adv Biomed Res"},{"issue":"6","key":"yoi220067r40","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/JCP.0000000000001289","article-title":"Comparison of rapid antidepressant and antisuicidal effects of intramuscular ketamine, oral ketamine, and electroconvulsive therapy in patients with major depressive disorder: a pilot study.","volume":"40","author":"Kheirabadi","year":"2020","journal-title":"J Clin Psychopharmacol"},{"key":"yoi220067r41","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jad.2020.07.066","article-title":"Antidepressant effects of ketamine and ECT: a pilot comparison.","volume":"276","author":"Sharma","year":"2020","journal-title":"J Affect Disord"},{"issue":"11","key":"yoi220067r42","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1176\/appi.ajp.2016.15081101","article-title":"Right unilateral ultrabrief pulse ECT in geriatric depression: phase 1 of the PRIDE study.","volume":"173","author":"Kellner","year":"2016","journal-title":"Am J Psychiatry"},{"issue":"4","key":"yoi220067r43","doi-asserted-by":"publisher","first-page":"485","DOI":"10.4088\/JCP.v65n0406","article-title":"Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report.","volume":"65","author":"Husain","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"yoi220067r44","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1176\/appi.ajp.2016.16010118","article-title":"A novel strategy for continuation ECT in geriatric depression: phase 2 of the PRIDE study.","volume":"173","author":"Kellner","year":"2016","journal-title":"Am J Psychiatry"},{"issue":"12","key":"yoi220067r45","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1038\/npp.2013.149","article-title":"Relapse following successful electroconvulsive therapy for major depression: a meta-analysis.","volume":"38","author":"Jelovac","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"yoi220067r46","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1001\/jama.285.10.1299","article-title":"Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial.","volume":"285","author":"Sackeim","year":"2001","journal-title":"JAMA"},{"issue":"9","key":"yoi220067r47","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial.","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"yoi220067r49","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19r12859","article-title":"Maintaining rapid antidepressant effects following ketamine infusion: a major unmet need.","volume":"81","author":"Papakostas","year":"2020","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"yoi220067r50","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12888-020-02672-3","article-title":"A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol.","volume":"20","author":"Phillips","year":"2020","journal-title":"BMC Psychiatry"},{"key":"yoi220067r51","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.cct.2018.12.009","article-title":"Electroconvulsive therapy (ECT) vs. ketamine in patients with treatment-resistant depression: the ELEKT-D study protocol.","volume":"77","author":"Mathew","year":"2019","journal-title":"Contemp Clin Trials"},{"issue":"2","key":"yoi220067r52","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1192\/bjp.2017.28","article-title":"Prediction of electroconvulsive therapy response and remission in major depression: meta-analysis.","volume":"212","author":"van Diermen","year":"2018","journal-title":"Br J Psychiatry"},{"key":"yoi220067r11","volume-title":"The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging: A Task Force Report of the American Psychiatric Association","author":"American Psychiatric Association","year":"2008"},{"key":"yoi220067r34","doi-asserted-by":"crossref","DOI":"10.7758\/9781610448864","volume-title":"The Handbook of Research Synthesis and Meta-analysis","author":"Cooper","year":"2019"},{"key":"yoi220067r48","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-3-319-42925-0_2","volume-title":"Ketamine for Treatment-Resistant Depression","author":"Fourcade","year":"2016"},{"key":"yoi220067r1","unstructured":"World Health Organization. Depression. Accessed January 6, 2020. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression"},{"key":"yoi220067r2","unstructured":"National Institute of Mental Health. Major depression. Accessed May 13, 2020. https:\/\/www.nimh.nih.gov\/health\/statistics\/major-depression.shtml"},{"key":"yoi220067r10","unstructured":"National Institute for Health and Care Excellence. Guidance on the use of electroconvulsive therapy. Published April 26, 2003. https:\/\/www.nice.org.uk\/guidance\/ta59"},{"key":"yoi220067r32","unstructured":"Cochrane Methods Bias. RoB 2: a revised Cochrane risk-of-bias tool for randomized trials. Accessed June 6, 2022. https:\/\/methods.cochrane.org\/bias\/resources\/rob-2-revised-cochrane-risk-bias-tool-randomized-trials"},{"key":"yoi220067r33","unstructured":"Cochrane Training. Cochrane Review Manager. Accessed June 6, 2022. https:\/\/training.cochrane.org\/online-learning\/core-software\/revman"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2797209\/jamapsychiatry_rhee_2022_oi_220067_1669908235.1183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T11:02:38Z","timestamp":1670410958000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2797209"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":52,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.3352","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,1]]}}}